A Global Leader in LAG-3 Immunotherapies for Cancer and Autoimmune Diseases
Immutep is a late clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.
Immutep’s diversified product portfolio harnesses LAG-3’s ability to stimulate the immune response to fight cancer or modulate it to combat autoimmune diseases.